Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.39 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.39 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.39 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 5/20 | 0.36 |
| ▸ | KDR | P35968 | 4/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30796022 | 1.00 | MEN1 (0.42) | MEN1KMT2AMAPTTP53RXFP1 | |
| SCHEMBL2069410 | 0.90 | KDR (0.46) | MEN1KMT2AMAPTSMN1; SMN2MAPK1 | |
| SCHEMBL30795492 | 0.89 | FFAR1 (0.42) | MEN1KMT2AMAPTTP53RXFP1 | |
| SCHEMBL2069424 | 0.89 | FFAR1 (0.42) | MEN1KMT2AMAPTTP53RXFP1 | |
| SCHEMBL30796256 | 0.89 | EGFR (0.47) | MEN1KMT2AMAPTSMN1; SMN2MAPK1 | |
| SCHEMBL2069771 | 0.89 | EGFR (0.47) | MEN1KMT2AMAPTSMN1; SMN2MAPK1 | |
| SCHEMBL2070409 | 0.87 | MEN1 (0.39) | MEN1KMT2ATP53SMN1; SMN2MAPK1 | |
| SCHEMBL30796593 | 0.87 | MEN1 (0.39) | MEN1KMT2ATP53SMN1; SMN2MAPK1 | |
| SCHEMBL2071916 | 0.87 | MEN1 (0.39) | MEN1KMT2ATP53SMN1; SMN2MAPK1 | |
| SCHEMBL30795637 | 0.87 | MEN1 (0.39) | MEN1KMT2ATP53SMN1; SMN2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256145-A1 | USE OF KCNQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED | H. LUNDBECK A/S (DK) | 2010-10-07 | — | — | US | claimed |
| EP-2185149-A1 | USE OF KNCQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED | H. Lundbeck A/S (DK) | 2010-05-19 | — | — | EP | claimed |
| WO-2009015667-A1 | USE OF KNCQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED | H. LUNDBECK A/S (DK) | 2009-02-05 | — | — | WO | claimed |
| US-20060183791-A1 | Substituted p-diaminobenzene derivatives | H. LUNDBECK A/S (DK) | 2006-08-17 | — | — | US | claimed |
| EP-1613303-A1 | SUBSTITUTED P-DIAMINOBENZENE DERIVATIVES | H. Lundbeck A/S (DK) | 2006-01-11 | — | — | EP | claimed |
| WO-2004082677-A1 | SUBSTITUTED P-DIAMINOBENZENE DERIVATIVES | H. LUNDBECK A/S (DK) | 2004-09-30 | — | — | WO | claimed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |
| EP-2554162-A1 | Use of KCNQ-Openers for Treating or Reducing the Symptoms of Schizophrenia | H. Lundbeck A/S (DK) | 2013-02-06 | — | — | EP | disclosed |
| US-7906537-B2 | Substituted p-diaminobenzene derivatives | H. LUNDBECK A/S (DK) | 2011-03-15 | — | — | US | disclosed |
| US-20100256145-A1 | USE OF KCNQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED | H. LUNDBECK A/S (DK) | 2010-10-07 | — | — | US | disclosed |
| EP-2185149-A1 | USE OF KNCQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED | H. Lundbeck A/S (DK) | 2010-05-19 | — | — | EP | disclosed |
| US-20090118285-A1 | USE OF KCNQ-OPENERS FOR TREATING OR REDUCING THE SYMPTOMS OF SCHIZOPHRENIA | H. LUNDBECK A/S (DK) | 2009-05-07 | — | — | US | disclosed |
| WO-2009015667-A1 | USE OF KNCQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED | H. LUNDBECK A/S (DK) | 2009-02-05 | — | — | WO | disclosed |
| EP-1983974-A1 | USE OF KCNQ-OPENERS FOR TREATING OR REDUCING THE SYMPTOMS OF SCHIZOPHRENIA | H. Lundbeck A/S (DK) | 2008-10-29 | — | — | EP | disclosed |
| WO-2007090409-A1 | USE OF KCNQ-OPENERS FOR THREATING OR REDUCING THE SYMPTOMS OF SCHIZOPHRENIA | H. LUNDBECK A/S (DK) | 2007-08-16 | — | — | WO | disclosed |
| US-20060183791-A1 | Substituted p-diaminobenzene derivatives | H. LUNDBECK A/S (DK) | 2006-08-17 | — | — | US | disclosed |
| EP-1613303-A1 | SUBSTITUTED P-DIAMINOBENZENE DERIVATIVES | H. Lundbeck A/S (DK) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004082677-A1 | SUBSTITUTED P-DIAMINOBENZENE DERIVATIVES | H. LUNDBECK A/S (DK) | 2004-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183791-A1 | Substituted p-diaminobenzene derivatives | ABCB1, UGT2B7, CYP2D6 | MEN1 1715/4885KMT2A 3706/4885MAPT 3488/4885 |
| US-20090118285-A1 | USE OF KCNQ-OPENERS FOR TREATING OR REDUCING THE SYMPTOMS OF SCHIZOPHRENIA | KCNQ4, KCNQ5, KCNQ1 | MEN1 4004/4885KMT2A 309/4885MAPT 1786/4885 |
| US-20100256145-A1 | USE OF KCNQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED | KCNQ2, KCNQ4, KCNQ1 | MEN1 1693/4885KMT2A 437/4885MAPT 1260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.